Ghada Nachabeh

ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome.

David Planchard, Nathalie Cozic, Marie Wislez et al. · Journal of Clinical Oncology · 2024 · 23 citations

Medicine, Oncology, Pharmacology +14

340O Efficacy, safety and biomarker analysis of ICARUS-BREAST01: A phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC)

Barbara Pistilli, Luisa Pierotti, M. Lacroix-Triki et al. · Annals of Oncology · 2024 · 21 citations · Full text

Medicine, Oncology, Pharmacology +16

189O A phase II study of patritumab deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01)

B. Pistilli, Nusaïbah Ibrahimi, M. Lacroix-Triki et al. · ESMO Open · 2023 · 19 citations · Full text

Medicine, Oncology, Pharmacology +17

Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial

Barbara Pistilli, Noémie Corcos, Livia Pierotti et al. · Nature Medicine · 2025 · 17 citations · Full text

Medicine, Oncology, Pharmacology +16